Evaluation of therapeutic strategies: A new method for balancing risk and benefit

Value in Health

Volumn 3, Issue 1, 2000, Pages 12-22

  Troche, Clemens J ^a   David Paltiel, A ^a   Makuch, Robert W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benefit risk assessment; Dose response relationships; Patient preferences; Pharmaceutical therapy

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANALGESIA; ARTICLE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

EID: 0034011470     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.31002.x     Document Type: Article

References (53)

1. AR Willan BJ O'brien DJ Cook Benefit-risk ratios in the assessment of the clinical evidence of a new therapy Controlled Clin Trials 18 1997 121 130
2. E Russek-Cohen Selecting the best dose when a monotonic dose–response relation exists Stat Med 13 1994 87 95
3. RJ Wills Basic pharmacodynamic concepts and models NR Cutler JJ Sramek PK Narang Pharmacodynamics and Drug Development Perspectives in Clinical Pharmacology 1994 John Wiley & Sons New York 3 18
4. AV Hill The possible effects of the aggregation of the molecules of hemoglobin on its dissociation curves J Phys 40 1910 iv vii
5. JG Wagner Kinetics of pharmacologic response. I: proposed relationship between response and drug concentration in the intact animal J Theor Biol 20 1968 173 201
6. NGH Holford LB Sheiner Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models Clin Pharmacokinet 6 1981 429 453
7. PS Price RE Keenan JC Swartout An approach for modeling noncancer dose responses with an emphasis on uncertainty Risk Anal 17 4 1997 427 437
8. RT O'neill Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization Stat Med 14 1995 1117 1127
9. C Gatsonis Bayesian methods for phase I clinical trials Stat Med 11 1992 1377 1389
10. S Moller An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses Stat Med 14 1995 911 922
11. J Bryant R Day Incorporating toxicity considerations into the design of two-stage phase II clinical trials Biometrics 51 1995 1372 1383
12. S Chevret The continual reassessment method in cancer phase I clinical trials: a simulation Stat Med 12 1993 1093 1108
13. PF Thall KE Russell A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials Biometrics 54 1998 251 264
14. MR Conaway GR Petroni Designs for phase II trials allowing for a tradeoff between response and toxicity Biometrics 52 1996 1375 1386
15. LL Miller Pitfalls in the drug approval process: dose-effect, experimental design, and risk-benefit issues Drug Information Journal 26 1992 251 260
16. C Chuang-Stein A new proposal for benefit-less-risk analysis in clinical trials Control Clin Trials 15 1994 30 43
17. K McPherson The best and the enemy of the good: randomized controlled trials, uncertainty, and assessing the role of patient choice in medical decision making J Epidemiol Community Health 48 1 1994 6 15
18. CL Kaufman Informed consent and patient decision making: two decades of research Soc Sci Med 17 1983 1657 1664
19. J Singh L Cuttler S Mincheol Medical decision-making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis Med Care 36 8 Suppl. 1998 AS31 AS45
20. PP Glasziou RJ Simes RD Gelber Quality adjusted survival analysis Stat Med 9 1990 1259 1276
21. RD Gelber BF Cole S Gelber The Q-TWiST B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 1996 Lippincott-Raven Publishers Philadelphia
22. RD Gelber A Goldhirsch A new endpoint for the assessment of adjuvant therapy in post-menopausal women with operable breast cancer J Clin Oncol 4 1986 1772 1779
23. RD Gelber WR Lenderking DJ Cotton Quality-of-life evaluation in a clinical trial of ziduvidine therapy in patients with mildly symptomatic HIV infection Ann Intern Med 116 1992 961 966
24. A Goldhirsch RD Gelber J Simes Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis J Clin Oncol 7 1989 36 44
25. AJ Martin TS Lumley RJ Simes Incorporating tradeoffs in quality of life assessment B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 1996 Lippincott-Raven Publishers Philadelphia
26. CE Schwartz BF Cole RD Gelber Measuring Patient-Centered Outcomes in Neurologic Disease Extending Q-Twist Method Arch Neurol 52 1995 754 762
27. CE Schwartz BF Cole BG Vickrey The Q-TWiST approach to assessing health-related quality of life in epilepsy Qual Life Res 4 1995 135 141
28. CE Schwartz L Coulthard-Morris B Cole The quality-of-life effects of Interferon Beta-1b in multiple sclerosis: an extended Q-TWiST analysis Arch Neurol 54 1997 1475 1480
29. J von Neumann O Morgenstern Theory of Games and Economic Behaviour 1944 Princeton University Press Princeton
30. R Luce H Raiffa Games and Decisions. Introduction and Critical Survey 1957 Wiley New York
31. S French Decision Theory: An Introduction to the Mathematics of Rationality 1986 Wiley London
32. RT Clemen Making Hard Decisions 1991 PWS-Kent Boston
33. GW Torrance Measurement of health state utilities for economic appraisal J Health Econ 5 1986 1 30
34. S Eriksen LR Keller A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents Med Decis Making 13 1993 118 125
35. RL Keeney H Raiffa Decisions with Multiple Objectives: Preferences and Value Tradeoffs 2nd ed ed. 1993 Cambridge University Press Cambridge
36. BJ Cohen Is expected utility theory normative for medical decision making? Med Decis Making 16 1996 1 6
37. RF Nease Do violations of the axioms of expected utility theory threaten decision analysis? Med Decis Making 16 1996 399 403
38. HA Llewellyn-Thomas MJ McGreal EC Thiel Patients' willingness to enter clinical trials: measuring the association with perceived benefits and preference for decision participation Soc Sci Med 32 1991 35 42
39. HA Llewellyn-Thomas EC Thiel RM Clark Patients versus surrogates: whose opinion counts on ethics review panels? Clin Res 37 1989 501 505
40. HA Llewellyn-Thomas JI Williams L Levy Using a tradeoff technique to assess patients' treatment preferences for benign hyperplasia Med Decis Making 16 1996 262 272
41. HA Llewellyn-Thomas Investigating patients' preferences for different treatment options Can J Nurs Res 29 3 1997 45 64
42. CD Naylor HA Llewellyn-Thomas Can there be a more patient-centered approach in determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol 47 1994 787 795
43. D Kahneman A Tversky Choices, values and frames Am Psychol 39 4 1984 341 350
44. D Kahneman A Tversky Prospect theory: an analysis of decision under risk Econometrica 47 1979 263 291
45. D Kahneman A Tversky The psychology of preferences Sci Am 246 1982 160 173
46. AM O'connor Effects of framing and level of probability on patients' preferences for cancer therapy J Clin Epidemiol 42 1989 119 126
47. BJ McNeil SG Pauker HC Sox On the elicitation of preferences for alternative therapies N Engl J Med 306 1982 1259 1262
48. TM Marteau Framing of information: its influence upon decisions of doctors and patients Br J Soc Psychol 28 1989 89 94
49. HA Llewellyn-Thomas JM McGreal EC Thiel Cancer patients' decision making and trial preferences: The effects of ‘framing’ information about short-term toxicity and long-term survival Med Decis Making 15 1995 4 12
50. ME Percy H Llewellyn-Thomas Assessing preferences about the DNR order: does it depend how you ask Med Decis Making 15 1995 209 216
51. TR Freeman MJ Bass Risk language preferred by mothers in considering a hypothetical new vaccine for their children Can Med Assoc J 147 1992 1013 1017
52. P Slovic S Lichtenstein Comparison of Bayesian regression approaches to the study of information processing judgement Organ Behav Hum Perform 6 1971 649 744
53. A Tversky D Kahneman Judgement under uncertainty: heuristics and biases Science 185 1974 1124 1131